This page summarises the type of evidence that exists for alprostadil. It is not a systematic review and does not cite specific trials.
Overview
Unlike many experimental compounds, alprostadil has an established evidence base that supports its regulatory approval. Its literature spans well-defined clinical uses and the underlying vascular pharmacology of prostaglandin E1. The maturity of that evidence is why alprostadil is an approved medicine rather than an investigational one.
Erectile dysfunction evidence
A substantial part of alprostadil's evidence concerns erectile dysfunction, where its ability to increase local blood flow and produce an erection is well-characterized. This body of work underpins the approved formulations used for that indication and their documented benefits and risks, including priapism.
Neonatal evidence
A distinctive strand of alprostadil's evidence base is its role in newborn medicine. Its use to maintain patency of the ductus arteriosus in certain ductal-dependent congenital heart defects is an established, approved application, reflecting reliable and clinically important vasodilatory action in that setting.
Broader vascular pharmacology
Beyond its two headline indications, prostaglandin E1 has been studied in the context of vascular and blood-flow physiology more generally. This reflects the fact that its core action, relaxing vascular smooth muscle, is relevant to several circulatory questions, even where use remains bounded by approved labeling.
Context and caveats
Alprostadil is comparatively well-supported for its approved uses, but an established evidence base is not a license for extrapolation. When reviewing the literature, consider the specific indication, the route studied, and the documented risks such as priapism and low blood pressure. Use should stay within approved indications and clinical judgment rather than being stretched to unproven applications.